| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | P50CDC37 |
| Entrez GeneID | 11140 |
| clone | 6B3B5 |
| WB Predicted band size | 44.5kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CDC37 (AA: 241-378) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CDC37抗体的参考文献及其摘要概述：
---
1. **"CDC37 is a molecular chaperone with specific functions in signal transduction"**
*Stepanova L, et al. (1996), Genes & Development*
摘要：研究揭示了CDC37作为HSP90共伴侣蛋白的功能，通过抗体介导的免疫沉淀实验证实其参与调控激酶(如CDK4)的稳定性，为后续癌症靶向研究奠定基础。
2. **"CDC37 regulates the stability of a kinase-interacting stathmin (KIS)/microtubule interaction network"**
*Bandhakavi S, et al. (2011), Molecular & Cellular Proteomics*
摘要：通过CDC37抗体敲低实验，证明其通过维持激酶组(如ERBB2、AKT)的稳定性影响细胞增殖，为靶向CDC37-HSP90轴的治疗策略提供依据。
3. **"Targeting the Hsp90-CDC37 interface in cancer"**
*Gray PJ, et al. (2008), Trends in Molecular Medicine*
摘要：综述CDC37在癌症中的过表达现象，强调利用抗体阻断CDC37-HSP90相互作用可抑制致癌激酶活性，推动相关抑制剂开发。
---
**注**：以上文献标题与内容为综合领域知识的概括，实际引用请以具体论文内容为准。如需最新文献，建议通过PubMed/Google Scholar以“CDC37 antibody”及“kinase chaperone”等关键词检索。
CDC37 antibodies are essential tools for studying the molecular chaperone CDC37. a critical regulator of protein kinase stability and activity. The CDC37 gene encodes a co-chaperone that specifically interacts with heat shock protein 90 (HSP90), forming a complex crucial for the maturation, stabilization, and functional activation of client proteins, particularly serine/threonine kinases like AKT, CDK4. and BRAF. This partnership enables HSP90 to selectively stabilize oncogenic kinases, positioning CDC37 as a key player in cancer biology and therapeutic targeting.
In research, CDC37 antibodies are widely used to investigate protein-protein interactions, chaperone-mediated folding mechanisms, and kinase signaling pathways. They enable applications such as Western blotting, immunoprecipitation, and immunohistochemistry to detect CDC37 expression patterns in normal vs. cancerous tissues. Elevated CDC37 levels are observed in prostate, breast, and hepatocellular carcinomas, correlating with poor prognosis and therapy resistance. Antibodies also facilitate studies exploring CDC37 inhibition as a strategy to destabilize oncogenic kinases and enhance chemotherapy efficacy.
Commercial CDC37 antibodies are typically raised against conserved epitopes in human or murine sequences, with validation across multiple platforms. Researchers must verify specificity due to potential cross-reactivity with other chaperones. Recent studies extend CDC37's role beyond cancer to neurodegenerative diseases and immune regulation, expanding the antibody's utility in diverse research contexts.
×
